CellRight Technologies to Participate in World’s Largest Spine Exhibition
25 October 2017 - 5:15AM
Business Wire
Company to showcase its product portfolio
products at the North American Spine Society meeting
Tissue Regenix Group plc (AIM:TRX) (‘Tissue Regenix’ or ‘The
Group’) the UK based regenerative medical devices company announces
subsidiary CellRight Technologies (‘CellRight’) will be
participating in The North American Spine Society annual meeting -
NASS 2017, being held in Orlando, Florida, October 25-28 2017.
NASS is the largest spine exhibition in the world where spine
care professionals from around the globe will share the latest
information on new technologies, innovative techniques and
procedures, and best practice.
NASS is the first conference that the Group have attended since
completing the acquisition of CellRight Technologies in August. The
Group will be exhibiting at booth #1343 promoting its range of
products including Matrix OI® stem cell containment products,
MatrixCellect 100 DBM putty, ConCelltrate Inductive Carrier Matrix
and Matrix OI Cortical Fibers.
CellRight is focused on innovative product development expanding
the potential of regenerative solutions in the osteobiologics
field, offering surgeons and patients a biologic product
portfolio.
With products that are 100% allograft bone, the innovative
platform technology preserves the native Bone Morphogenic Proteins
(BMPs) and growth-factors to verify osteoinductivity needed for
bone regeneration, resulting in best-in-class products and ensuring
superior clinical outcomes. CellRight verifies osteoinductivity for
every lot post sterilization and these osteogenic bioengineered
implants address indications in the spine, trauma, TJA and sports
medicine fields.
The CellRight technology complements dCELL® Technology, Tissue
Regenix’ patented decellularization process for soft tissues. In
due course, soft tissue products for use in various orthopedics
applications, with an initial focus on ligament reconstruction,
will also be processed at the state-of-the-art CellRight tissue
bank facility based in San Antonio, Texas.
Jesus Hernandez, CEO CellRight Technologies commented: “We are
delighted to be attending NASS as part of the larger Tissue Regenix
Group. This conference offers a unique opportunity to showcase our
portfolio of innovative spinal products and discuss the future
potential of the combined CellRight and dCELL® platforms with some
of the best healthcare specialists in the world.”
###
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL®') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a
multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies®,
a biotech company that specializes in regenerative medicine and is
dedicated to the development of innovative osteoinductive and wound
care scaffolds that enhance healing opportunities of defects
created by trauma and disease.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171024006526/en/
For more information:Tissue Regenix Group
plcCaitlin PearsonHead of CommunicationsTel: 0330 430
3073orRacepoint GlobalJeff Stoecker,
+1-617-624-3424jstoecker@racepointglobal.com
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024